Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the ...

Following a year of collaboration under a joint venture agreement, US-based TKI and Cyprus-based Hybrid ConsulTech have merged operations and will now formally operate under the unified TKI brand ...

JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently ...

NSCLC: Added Support for TKI Regimen Given With Anti-Angiogenic Therapy – Significant PFS, translating into additional benefit of 9.2 months vs TKI alone ...

The study examined a single injection of OTX-TKI (axitinib intravitreal implant, Ocular Therapeutix) vs. sham in reducing intraretinal fluid.

Abbreviations: 2G, second-generation; CML, chronic myeloid leukemia; CP, chronic phase; TKI, tyrosine kinase inhibitor. The 2G-TKI nilotinib has increased potency compared with imatinib but generally ...

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

PSMA may be a noninvasive biomarker for predicting treatment response in metastatic clear cell renal cell carcinoma (RCC).

Neoadjuvant TKI treatment in non-metastatic GIST patients led to less complex surgery, with tumor size reduction within three months predicting benefit.

Advances in tyrosine kinase inhibitors yielded robust options for CML, raising questions about US accelerated approval for the frontline use of asciminib in this indication.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy — Better OS, PFS, response rate, but newer combination strategies not included ...